Artivion Reports Second Quarter 2026 Financial Results
Artivion reported second quarter revenue of $125.8 million, up 11% year-over-year, driven by 18% growth in On-X mechanical heart valves and 12% growth in stent grafts. During the quarter, the company achieved two major strategic milestones: the completion of the Endospan acquisition and the U.S. FDA PMA approval of the AMDS Hybrid Prosthesis.
Key figures
- Revenue
- $125.8 million
- Guidance
- FY2026 revenue $480-$496 million, adjusted EBITDA $92-$99 million
- Revenue Yoy
- 11%
- Non gaap eps
- 0.13
- Adjusted ebitda
- $26.4 million
- Non gaap net income
- $6.3 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.